source
- Lilly uses indirect data to argue its oral GLP-1 pill may outperform Novo’s semaglutideEli Lilly’s weight‑loss drug Foundayo has seen a slower launch than expected, according to BMO Capital Markets, which noted the product is lagging behind competitors. To bolster its market case, L…
- Beam Therapeutics sues rival YolTech over alleged theft of base-editing data for AATD therapyBeam Therapeutics, a base editing biotech, filed a lawsuit in U.S. District Court in Massachusetts against YolTech Therapeutics and former employee Zi Jun (Emma) Wang, alleging theft of proprietary…